

# Patricia Pautier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3094037/publications.pdf>

Version: 2024-02-01

30  
papers

734  
citations

687363

13  
h-index

552781

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

995  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. <i>Fertility and Sterility</i> , 2016, 106, 1195-1211.e5.	1.0	160
2	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016, 141, 454-460.	1.4	85
3	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type—Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020, 26, 3908-3917.	7.0	82
4	Gynecologic Cancer InterGroup (GCIg) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S73-S77.	2.5	53
5	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38
6	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	5.5	35
7	Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 964-970.	1.5	34
8	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Small Cell Cancers. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S30-S34.	2.5	31
9	Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. <i>Gynecologic Oncology Reports</i> , 2017, 22, 21-25.	0.6	31
10	Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis. <i>Cells</i> , 2020, 9, 1496.	4.1	29
11	Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors. <i>Oncologist</i> , 2019, 24, 702-709.	3.7	28
12	Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact. <i>Radiotherapy and Oncology</i> , 2016, 120, 460-466.	0.6	22
13	Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. <i>Gynecologic Oncology</i> , 2021, 160, 279-284.	1.4	18
14	Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers. <i>Oncologist</i> , 2018, 23, 324-327.	3.7	17
15	Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 885-891.	2.8	9
16	Cervical Cancer and Fertility-Sparing Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4825.	2.4	9
17	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	1.8	8
18	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. <i>British Journal of Cancer</i> , 2020, 122, 564-568.	6.4	8

#	ARTICLE	IF	CITATIONS
19	Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT). <i>Gynecologic Oncology</i> , 2020, 159, 129-135.	1.4	8
20	Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 775-785.	3.3	6
21	Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. <i>Oncologist</i> , 2017, 22, 182-188.	3.7	6
22	A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 534-538.	1.4	5
23	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. <i>Gynecologic Oncology</i> , 2021, 163, 64-71.	1.4	3
24	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5613-TPS5613.	1.6	3
25	A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5614-TPS5614.	1.6	3
26	Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5514-5514.	1.6	2
27	Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?. <i>Gynecologic Oncology Reports</i> , 2017, 22, 52-54.	0.6	1
28	Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5552-5552.	1.6	0
29	Low skeletal muscle density as predictive for febrile neutropenia in patients treated by doxorubicin/trabectedin/pegfilgrastim combination as a first-line treatment of advanced or metastatic leiomyosarcoma (LMS) (LMS02 study).. <i>Journal of Clinical Oncology</i> , 2014, 32, e20640-e20640.	1.6	0
30	Neoadjuvant chemotherapy in fertility-sparing management of FIGO 2018 stage IB2 cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 680-685.	2.5	0